The Filings Report

Exelixis Inc

EXELNasdaqCIK 939767Healthcare / Biotechnologyfiscal year ends December67 quarters since 2010

Revenue, Q3 FY2026
$659M
+10.2% on Q3 FY2025
Net income
$218M
+12.7% on Q3 FY2025
Free cash flow
$277M
−3.9% on Q3 FY2025
Diluted EPS
$0.85
+23.2% on Q3 FY2025
Revenue, TTM
$2.5B
trailing four quarters
Net margin, TTM
35.5%
net income $885M
Free cash flow, TTM
$1.2B
$1.2B less $12M capex
Cash and equivalents
$305M
long-term debt —, Oct 2, 2026
Shares, 12-month change
−9.0%
244M shares, Oct 2, 2026
Buybacks, TTM
$1.3B
7.5% of market value
Dividends, TTM
—
no yield
Market value
$16.9B
at the close, buybacks

Latest quarter Q3 FY2026, filed October 29, 2026. Trailing figures sum the latest four quarters. Market values at the latest close, from a market data vendor.

In Q3 FY2026, the quarter ended October 2, 2026, Exelixis Inc reported revenue of $659M, +10.2% on Q3 FY2025, and net income of $218M (+12.7%). Operating margin was 40.8%. Free cash flow, operating cash flow less capital expenditures, was $277M ($280M less $2M). Diluted earnings per share were $0.85.

The last 16 quarters

Q4 FY2022 to Q3 FY2026, through the filing of October 29, 2026.

Revenue and net incomeRevenueNet income
−$200M$0$200M$400M$600M$800MQ4'22, Revenue: $424MQ4'22, Net income: −$30MQ4'22Q1'23, Revenue: $409MQ1'23, Net income: $40MQ1'23Q2'23, Revenue: $470MQ2'23, Net income: $81MQ2'23Q3'23, Revenue: $472MQ3'23, Net income: $1MQ3'23Q4'23, Revenue: $480MQ4'23, Net income: $86MQ4'23Q1'24, Revenue: $425MQ1'24, Net income: $37MQ1'24Q2'24, Revenue: $637MQ2'24, Net income: $226MQ2'24Q3'24, Revenue: $540MQ3'24, Net income: $118MQ3'24Q4'24, Revenue: $567MQ4'24, Net income: $140MQ4'24Q1'25, Revenue: $555MQ1'25, Net income: $160MQ1'25Q2'25, Revenue: $568MQ2'25, Net income: $185MQ2'25Q3'25, Revenue: $598MQ3'25, Net income: $194MQ3'25Q4'25, Revenue: $599MQ4'25, Net income: $245MQ4'25Q1'26, Revenue: $611MQ1'26, Net income: $210MQ1'26Q2'26, Revenue: $629MQ2'26, Net income: $212MQ2'26Q3'26, Revenue: $659MQ3'26, Net income: $218MQ3'26−$200M$0$200M$400M$600M$800MQ4'22, Revenue: $424MQ4'22, Net income: −$30MQ1'23, Revenue: $409MQ1'23, Net income: $40MQ1'23Q2'23, Revenue: $470MQ2'23, Net income: $81MQ3'23, Revenue: $472MQ3'23, Net income: $1MQ3'23Q4'23, Revenue: $480MQ4'23, Net income: $86MQ1'24, Revenue: $425MQ1'24, Net income: $37MQ1'24Q2'24, Revenue: $637MQ2'24, Net income: $226MQ3'24, Revenue: $540MQ3'24, Net income: $118MQ3'24Q4'24, Revenue: $567MQ4'24, Net income: $140MQ1'25, Revenue: $555MQ1'25, Net income: $160MQ1'25Q2'25, Revenue: $568MQ2'25, Net income: $185MQ3'25, Revenue: $598MQ3'25, Net income: $194MQ3'25Q4'25, Revenue: $599MQ4'25, Net income: $245MQ1'26, Revenue: $611MQ1'26, Net income: $210MQ1'26Q2'26, Revenue: $629MQ2'26, Net income: $212MQ3'26, Revenue: $659MQ3'26, Net income: $218MQ3'26

Net income losses drawn in red.

Free cash flow
−$100M$0$100M$200M$300M$400MQ4'22, Free cash flow: $64MQ4'22Q1'23, Free cash flow: $72MQ1'23Q2'23, Free cash flow: $115MQ2'23Q3'23, Free cash flow: $108MQ3'23Q4'23, Free cash flow: −$3MQ4'23Q1'24, Free cash flow: $59MQ1'24Q2'24, Free cash flow: $113MQ2'24Q3'24, Free cash flow: $263MQ3'24Q4'24, Free cash flow: $236MQ4'24Q1'25, Free cash flow: $208MQ1'25Q2'25, Free cash flow: $46MQ2'25Q3'25, Free cash flow: $289MQ3'25Q4'25, Free cash flow: $332MQ4'25Q1'26, Free cash flow: $250MQ1'26Q2'26, Free cash flow: $301MQ2'26Q3'26, Free cash flow: $277MQ3'26−$100M$0$100M$200M$300M$400MQ4'22, Free cash flow: $64MQ1'23, Free cash flow: $72MQ1'23Q2'23, Free cash flow: $115MQ3'23, Free cash flow: $108MQ3'23Q4'23, Free cash flow: −$3MQ1'24, Free cash flow: $59MQ1'24Q2'24, Free cash flow: $113MQ3'24, Free cash flow: $263MQ3'24Q4'24, Free cash flow: $236MQ1'25, Free cash flow: $208MQ1'25Q2'25, Free cash flow: $46MQ3'25, Free cash flow: $289MQ3'25Q4'25, Free cash flow: $332MQ1'26, Free cash flow: $250MQ1'26Q2'26, Free cash flow: $301MQ3'26, Free cash flow: $277MQ3'26

Operating cash flow less capital expenditures; negative quarters in red.

Cash and equivalents against long-term debtCash and equivalentsLong-term debt
$0$200M$400M$600MQ4'22, Cash and equivalents: $501MQ4'22Q1'23, Cash and equivalents: $541MQ1'23Q2'23, Cash and equivalents: $464MQ2'23Q3'23, Cash and equivalents: $397MQ3'23Q4'23, Cash and equivalents: $263MQ4'23Q1'24, Cash and equivalents: $260MQ1'24Q2'24, Cash and equivalents: $198MQ2'24Q3'24, Cash and equivalents: $258MQ3'24Q4'24, Cash and equivalents: $217MQ4'24Q1'25, Cash and equivalents: $184MQ1'25Q2'25, Cash and equivalents: $164MQ2'25Q3'25, Cash and equivalents: $376MQ3'25Q4'25, Cash and equivalents: $482MQ4'25Q1'26, Cash and equivalents: $226MQ1'26Q2'26, Cash and equivalents: $281MQ2'26Q3'26, Cash and equivalents: $305MQ3'26$0$200M$400M$600MQ4'22, Cash and equivalents: $501MQ1'23, Cash and equivalents: $541MQ1'23Q2'23, Cash and equivalents: $464MQ3'23, Cash and equivalents: $397MQ3'23Q4'23, Cash and equivalents: $263MQ1'24, Cash and equivalents: $260MQ1'24Q2'24, Cash and equivalents: $198MQ3'24, Cash and equivalents: $258MQ3'24Q4'24, Cash and equivalents: $217MQ1'25, Cash and equivalents: $184MQ1'25Q2'25, Cash and equivalents: $164MQ3'25, Cash and equivalents: $376MQ3'25Q4'25, Cash and equivalents: $482MQ1'26, Cash and equivalents: $226MQ1'26Q2'26, Cash and equivalents: $281MQ3'26, Cash and equivalents: $305MQ3'26

Positions at each quarter end, as filed; short-term investments are not included.

Income statement

Last eight quarters, newest first, through Q3 FY2026 filed October 29, 2026.

Exelixis Inc income statement, quarterly
Millions of dollarsQ3 FY2026ended Oct 2, 2026filed Oct 29, 2026Q2 FY2026ended Jul 3, 2026filed Aug 5, 2026Q1 FY2026ended Apr 3, 2026filed May 5, 2026Q4 FY2025ended Jan 2, 2026filed Feb 10, 2026Q3 FY2025ended Oct 3, 2025filed Nov 4, 2025Q2 FY2025ended Jul 4, 2025filed Jul 28, 2025Q1 FY2025ended Apr 4, 2025filed May 13, 2025Q4 FY2024ended Jan 3, 2025filed Feb 11, 2025YoYQ3 FY2026vs Q3 FY2025
Revenue659629611599598568555567+10.2%
Cost of revenue2621202619191920+41.2%
Gross profit—————————
Research and development209212200213199200212249+5.2%
Selling, general and administrative155148140123124135137134+25.0%
Operating income268248251235237214187163+13.5%
Other income (expense)00000000+195.9%
Pretax income—————————
Income tax655157859464645+10.0%
Net income218212210245194185160140+12.7%
Diluted EPS ($)0.850.820.79—0.690.650.55—+23.2%
Diluted shares (millions)256260267—279284288——

Fourth quarters are the fiscal year less the first nine months when the filer reports no discrete fourth quarter, and are marked. Diluted EPS is never derived, so a derived quarter shows none. Italic figures are derived.

Balance sheet

Last eight quarters, newest first, through Q3 FY2026 filed October 29, 2026.

Exelixis Inc balance sheet, quarterly
Millions of dollarsQ3 FY2026ended Oct 2, 2026filed Oct 29, 2026Q2 FY2026ended Jul 3, 2026filed Aug 5, 2026Q1 FY2026ended Apr 3, 2026filed May 5, 2026Q4 FY2025ended Jan 2, 2026filed Feb 10, 2026Q3 FY2025ended Oct 3, 2025filed Nov 4, 2025Q2 FY2025ended Jul 4, 2025filed Jul 28, 2025Q1 FY2025ended Apr 4, 2025filed May 13, 2025Q4 FY2024ended Jan 3, 2025filed Feb 11, 2025YoYQ3 FY2026vs Q3 FY2025
Cash and equivalents305281226482376164184217−19.0%
Short-term investments587558551577612627848894−4.1%
Total current assets1,3221,2511,2091,4431,4021,1811,3971,468−5.8%
Total assets2,5132,4942,5942,8442,8242,6782,8372,948−11.0%
Total current liabilities412362371406374336399404+10.2%
Long-term debt—————————
Total liabilities680650658683663645706703+2.5%
Stockholders’ equity1,8341,8441,9362,1612,1612,0342,1312,244−15.1%
Shares outstanding (millions)244248251260268269273280—

Positions at each period end. Nothing on this statement is derived. Long-term debt is the filed noncurrent line only; no total-debt composite is constructed across filers. Italic figures are derived.

Cash flow statement

Last eight quarters, newest first, through Q3 FY2026 filed October 29, 2026.

Exelixis Inc cash flow statement, quarterly
Millions of dollarsQ3 FY2026ended Oct 2, 2026filed Oct 29, 2026Q2 FY2026ended Jul 3, 2026filed Aug 5, 2026Q1 FY2026ended Apr 3, 2026filed May 5, 2026Q4 FY2025ended Jan 2, 2026filed Feb 10, 2026Q3 FY2025ended Oct 3, 2025filed Nov 4, 2025Q2 FY2025ended Jul 4, 2025filed Jul 28, 2025Q1 FY2025ended Apr 4, 2025filed May 13, 2025Q4 FY2024ended Jan 3, 2025filed Feb 11, 2025YoYQ3 FY2026vs Q3 FY2025
Operating cash flow28030825233429049211240−3.6%
Capital expenditures27211334+67.9%
Free cash flow (CFO − capex)27730125033228946208236−3.9%
Depreciation and amortization77777778−6.6%
Share repurchases250323430258104302284190+140.3%
Dividends paid—————————

10-Qs file cash flows as year-to-date totals, so quarterly figures are differenced from consecutive filings and marked. Free cash flow is operating cash flow less capital expenditures, computed from the two filed lines. Italic figures are derived.

Annual statements

Every fiscal year filed, newest first, through FY2025 filed February 10, 2026.

Income statement

Exelixis Inc income statement, annual
Millions of dollarsFY2025ended Jan 2, 2026filed Feb 10, 2026FY2024ended Jan 3, 2025filed Feb 11, 2025FY2023ended Dec 29, 2023filed Feb 6, 2024FY2022ended Dec 30, 2022filed Feb 7, 2023FY2021ended Dec 31, 2021filed Feb 18, 2022FY2020ended Jan 1, 2021filed Feb 11, 2021FY2019ended Jan 3, 2020filed Feb 25, 2020FY2018ended Dec 28, 2018filed Feb 22, 2019FY2017ended Dec 29, 2017filed Feb 26, 2018FY2016ended Dec 30, 2016filed Feb 26, 2018FY2015ended Dec 31, 2015filed Feb 29, 2016FY2014ended Dec 31, 2014filed Mar 2, 2015FY2013ended Dec 31, 2013filed Feb 20, 2014FY2012ended Dec 31, 2012filed Feb 21, 2013FY2011ended Dec 31, 2011filed Feb 22, 2012FY2010ended Dec 31, 2010filed Aug 4, 2011FY2009ended Dec 31, 2009filed Aug 4, 2011
Revenue2,3202,1691,8301,6111,43598896885445219137253147290185152
Cost of revenue8476735853363326157———————
Gross profit—————————————————
Research and development8259101,0448926945483371821129696189179129157211235
Selling, general and administrative51949254346040229322820615911657515132333334
Operating income872605171201287110369439166(28)(121)(224)(201)(122)90(91)(122)
Other income (expense)00000110(7)(42)(40)(37)(38)(23)(13)(1)(19)
Pretax income—————131398452159(70)(162)(261)(245)(148)77(92)(141)
Income tax1591605052631977(238)40000010(1)
Net income783521208182231112321690154(70)(162)(261)(238)(145)76(92)(135)
Diluted EPS ($)2.781.760.650.560.720.351.022.210.49(0.28)(0.77)—(1.33)(0.92)0.58(0.85)(1.26)
Diluted shares (millions)282296321325322318315313312251209—184160130109107

Balance sheet

Exelixis Inc balance sheet, annual
Millions of dollarsFY2025ended Jan 2, 2026filed Feb 10, 2026FY2024ended Jan 3, 2025filed Feb 11, 2025FY2023ended Dec 29, 2023filed Feb 6, 2024FY2022ended Dec 30, 2022filed Feb 7, 2023FY2021ended Dec 31, 2021filed Feb 18, 2022FY2020ended Jan 1, 2021filed Feb 11, 2021FY2019ended Jan 3, 2020filed Feb 25, 2020FY2018ended Dec 28, 2018filed Feb 22, 2019FY2017ended Dec 29, 2017filed Feb 26, 2018FY2016ended Dec 30, 2016filed Feb 26, 2018FY2015ended Dec 31, 2015filed Feb 29, 2016FY2014ended Dec 31, 2014filed Mar 2, 2015FY2013ended Dec 31, 2013filed Feb 20, 2014FY2012ended Dec 31, 2012filed Feb 21, 2013FY2011ended Dec 31, 2011filed Feb 22, 2012FY2010ended Dec 31, 2010filed Aug 4, 2011FY2009ended Dec 31, 2009filed Aug 4, 2011
Cash and equivalents48221726350164731926731518315214280104170749787
Short-term investments577894732807820887586379205268256413824112065—
Total current assets1,4431,4681,3181,6191,8351,4451,011897485469179167267433229183—
Total assets2,8442,9482,9423,0712,6162,1371,8861,422655596332323503721393361—
Total current liabilities40640439432433820514310511526952170888292200—
Long-term debt————————0189418259335323177171—
Total liabilities683703678583406258200135370506473483483476303589—
Stockholders’ equity2,1612,2442,2642,4882,2111,8791,6861,28728589———————
Shares outstanding (millions)260280303324319312305300296291228196195184148——

Cash flow statement

Exelixis Inc cash flow statement, annual
Millions of dollarsFY2025ended Jan 2, 2026filed Feb 10, 2026FY2024ended Jan 3, 2025filed Feb 11, 2025FY2023ended Dec 29, 2023filed Feb 6, 2024FY2022ended Dec 30, 2022filed Feb 7, 2023FY2021ended Dec 31, 2021filed Feb 18, 2022FY2020ended Jan 1, 2021filed Feb 11, 2021FY2019ended Jan 3, 2020filed Feb 25, 2020FY2018ended Dec 28, 2018filed Feb 22, 2019FY2017ended Dec 29, 2017filed Feb 26, 2018FY2016ended Dec 30, 2016filed Feb 26, 2018FY2015ended Dec 31, 2015filed Feb 29, 2016FY2014ended Dec 31, 2014filed Mar 2, 2015FY2013ended Dec 31, 2013filed Feb 20, 2014FY2012ended Dec 31, 2012filed Feb 21, 2013FY2011ended Dec 31, 2011filed Feb 22, 2012FY2010ended Dec 31, 2010filed Aug 4, 2011FY2009ended Dec 31, 2009filed Aug 4, 2011
Operating cash flow884700333363401209527416166206(141)(235)(199)(123)(159)(101)(15)
Capital expenditures8284028543013332120023126
Free cash flow (CFO − capex)876672293335347179514382144205(141)(236)(201)(126)(160)(103)(20)
Depreciation and amortization292926211498511123671113
Share repurchases94865255000————————————
Dividends paid—————————————————

Insider activity

Form 4 filings by officers, directors and 10% owners, November 1, 2024 to November 1, 2026. Only open-market purchases and sales count as buys and sells; awards, exercises, tax withholding and gifts are listed in grey and never counted.

Bought, three months
$0
0 purchases by 0 insiders; officers and directors $0
Sold, three months
$527K
1 sales by 1 insider; officers and directors $527K
Bought, twelve months
$1M
1 purchases by 1 insider; officers and directors $1M
Sold, twelve months
$42M
32 sales by 12 insiders; officers and directors $42M

The last 25 transactions

TradedInsiderRoleTransactionSharesPriceValueHeld afterFiled
Aug 10, 2026Beckerle Mary CDirectoropen-market sale10b5-19,812$53.66$527K16,079Aug 12, 2026
Jun 1, 2026Wyszomierski Jack LDirectoropen-market sale10b5-13,925$50.55$198K284,384Jun 3, 2026
Jun 1, 2026Eckhardt Sue GailDirectoropen-market sale10b5-19,812$50.14$492K16,079Jun 3, 2026
May 27, 2026Papadopoulos SteliosDirectoraward8,367$0.00—1MMay 29, 2026
May 27, 2026Heyman Tomas J.Directoraward8,367$0.00—50,649May 29, 2026
May 27, 2026Eckhardt Sue GailDirectoraward8,367$0.00—25,891May 29, 2026
May 27, 2026Smith JulieDirectoraward8,367$0.00—28,957May 29, 2026
May 27, 2026Freire Maria CDirectoraward8,367$0.00—109,186May 29, 2026
May 27, 2026Beckerle Mary CDirectoraward8,367$0.00—25,891May 29, 2026
May 27, 2026Oliver BobDirectoraward8,367$0.00—29,487May 29, 2026
May 27, 2026Wyszomierski Jack LDirectoraward8,367$0.00—288,309May 29, 2026
May 27, 2026Poste GeorgeDirectoraward8,367$0.00—127,199May 29, 2026
May 26, 2026Aftab DanaEVP, Research and Developmentopen-market sale43,451$50.35$2M594,741May 28, 2026
May 20, 2026Haley Patrick J.EVP, Commercialopen-market sale32,110$49.81$2M357,638May 22, 2026
May 18, 2026Morrissey MichaelPresident and CEO, Directorgift124,047$0.00—1MMay 19, 2026
May 18, 2026Morrissey MichaelPresident and CEO, Directorgiftindirect124,047$0.00—2MMay 19, 2026
May 18, 2026Senner Christopher J.EVP and CFOopen-market sale34,901$50.00$2M952,317May 19, 2026
May 18, 2026Hefti BrendaSVP and General Counselopen-market sale10b5-16,625$50.21$333K106,762May 19, 2026
May 15, 2026Morrissey MichaelPresident and CEO, Directortax withholding128,497$51.10$7M1MMay 19, 2026
May 15, 2026Senner Christopher J.EVP and CFOtax withholding40,892$51.10$2M987,218May 19, 2026
May 15, 2026Haley Patrick J.EVP, Commercialtax withholding33,265$51.10$2M389,748May 19, 2026
May 15, 2026Hefti BrendaSVP and General Counseltax withholding6,411$51.10$328K113,387May 19, 2026
May 15, 2026Aftab DanaEVP, Research and Developmenttax withholding30,578$51.10$2M638,192May 19, 2026
May 7, 2026Beckerle Mary CDirectoroption exercise3,856$23.24$90K25,236May 8, 2026
May 7, 2026Beckerle Mary CDirectoropen-market sale7,712$48.45$374K17,524May 8, 2026

Full insider history for Exelixis Inc, or insider activity across all companies. A record of filings, not a recommendation.

Sources

Fiscal year ends in month 12; periods are labeled with the issuer's own fiscal calendar. Values are as most recently filed (restatements apply; per-share values are on current split basis per the connector's split table, flagged in adjusted). Flow items flagged in `derived` were computed (Q4 = FY − nine months; quarterly cash flow differenced from year-to-date filings) rather than read from a filing. `reconciliation.repaired` lists periods where a full-year figure was filed in a quarter slot: that row was dropped and the quarter rebuilt from the annual figure. `reconciliation.quarantined` lists periods where four filed quarters do not sum to the filed year — those quarterly values are withheld, so a blank there is a withholding rather than an absence of reporting.

Filer
EXELIXIS, INC., CIK 939767 on EDGAR
Extract generated
November 1, 2026
Withheld
4 line-years whose four quarters do not sum to the filed year: net income FY2012, net income FY2013, net income FY2014, other income FY2015
Repaired
2 quarters where a full-year figure was filed in a quarter slot and the quarter was rebuilt: other income FY2018, other income FY2024
XBRL concepts behind each line

Income statement

Revenue: RevenueFromContractWithCustomerExcludingAssessedTax, Revenues, SalesRevenueNet
Cost of revenue: CostOfGoodsAndServicesSold
Gross profit: GrossProfit
Research and development: ResearchAndDevelopmentExpense
Selling, general and administrative: GeneralAndAdministrativeExpense, SellingGeneralAndAdministrativeExpense
Operating income: OperatingIncomeLoss
Other income (expense): NonoperatingIncomeExpense, OtherNonoperatingIncomeExpense
Pretax income: IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
Income tax: IncomeTaxExpenseBenefit
Net income: NetIncomeLoss
Diluted EPS ($): EarningsPerShareDiluted
Diluted shares (millions): WeightedAverageNumberOfDilutedSharesOutstanding

Balance sheet

Cash and equivalents: CashAndCashEquivalentsAtCarryingValue
Short-term investments: MarketableSecuritiesCurrent, ShortTermInvestments
Total current assets: AssetsCurrent
Total assets: Assets
Total current liabilities: LiabilitiesCurrent
Long-term debt: LongTermDebt, LongTermDebtNoncurrent
Total liabilities: Liabilities
Stockholders’ equity: StockholdersEquity
Shares outstanding (millions): dei:EntityCommonStockSharesOutstanding

Cash flow statement

Operating cash flow: NetCashProvidedByUsedInOperatingActivities
Capital expenditures: PaymentsToAcquirePropertyPlantAndEquipment
Free cash flow (CFO − capex): not filed
Depreciation and amortization: DepreciationDepletionAndAmortization
Share repurchases: PaymentsForRepurchaseOfCommonStock
Dividends paid: not filed

The data

The statements on this page as files, generated November 1, 2026.

JSON file
/data/financials/EXEL.json